Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly.
OBJECTIVE
Acromegaly has an important impact on quality of life (QOL). The aim of this study was to evaluate the associations of remission status and lanreotide treatment with QOL in patients with treated acromegaly, by the newly developed disease-generated acromegaly QOL questionnaire (ACROQOL).


METHODS
Cross-sectional study.


METHODS
Fifty-two patients with treated acromegaly were recruited to complete the Chinese version of the ACROQOL translated and validated from the English version. These patients were divided into controlled and uncontrolled groups based on the latest remission criteria and further subdivided into four groups according to the present treatment with lanreotide or not. Comparisons between groups were analyzed.


RESULTS
There was no difference between controlled and uncontrolled groups in the ACROQOL scores of total score, both scales and psychological subscales. However, in the controlled group, present treatment with lanreotide, in comparison with no treatment, showed worse ACROQOL scores in total score (P = 0.021), psychological scale (P = 0.011), psychological subscale 'appearance' (P = 0.032) and 'personal relations' (P = 0.010).


CONCLUSIONS
The lanreotide treatment was negatively associated with QOL in biochemically controlled acromegalic patients, especially in the psychological aspect.
Hua
Shih-Che
SC
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chia-Yi Christian Hospital, No 539, Jhongsiao Road, Chiayi City, Taiwan.
Yan
Yuan-Horng
YH
Chang
Tien-Chun
TC
D000172:Acromegaly / Q000188:drug therapy* / Q000523:psychology*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D012074:Remission Induction; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin